Onur Selcuk Yigit

Dr. Onur Selcuk Yigit

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SGSELİN GENÇ
SELİN GENÇ
BEBahri Evren
Bahri Evren
OYOnur Selcuk Yigit
Onur Selcuk Yigit
ISIbrahim Sahin
Ibrahim Sahin
RDRamazan Dayanan
Ramazan Dayanan
FMFiliz Mercantepe
Filiz Mercantepe
Background/Objectives: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA. Methods: A total of 51 individuals with a diagnosis of DKA were included in the trial; 19 of these patients were treated with SGLT2-is, while 32 were not. Patients diagnosed with DKA and treated with SGLT2-is were compared to those not treated with the medication in terms of clinical, biochemical, and laboratory characteristics. Results: The age of patients utilizing SGLT2-is was statistically considerably greater than that of non-users (p < 0.001). EuDKA was exclusively noted in the SGLT2-is cohort (p = 0.005). Urinary tract infections, vulvovaginitis, and genitourinary infections were substantially more prevalent among SGLT2-i users compared with non-users among both women and the overall patient group (p = 0.036, p = 0.001, p = 0.005, p = 0.003, respectively). Plasma glucose concentrations were significantly higher in SGLT2-i non-users (p = 0.006). Chloride (Cl−) concentrations were elevated among SGLT2-i users (p = 0.036). Conclusions: The study findings indicate that SGLT2 inhibitors may substantially influence age, serum chloride, EuDKA, and the occurrence of genitourinary infections in individuals with DKA.

9 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MUMehmet Fatih Uzanulu
Mehmet Fatih Uzanulu
MAMusa Ak
Musa Ak
LBLevent Bolat
Levent Bolat
OYOnur Selcuk Yigit
Onur Selcuk Yigit
CUCihat Uçar
Cihat Uçar
HSHandan Kanat Seyhan
Handan Kanat Seyhan
Background/Objectives: Asprosin is a fasting-induced glucogenic adipokine with pro-inflammatory effects in experimental models, but its behaviour in acute pancreatitis (AP) is unknown. In this exploratory study, we examined whether circulating asprosin differs between patients with AP and healthy controls, how it changes during hospitalisation and whether it is associated with disease severity. Methods: In this prospective case–control study, 82 patients with AP (of 183 screened, after exclusion of diabetes, hypertriglyceridaemia and morbid obesity) and 82 sex-matched healthy controls were enrolled. Serum asprosin was measured by ELISA at admission, 72 h and 120 h in patients and once in fasting controls. Severity was defined by the revised Atlanta classification. Because patients were older and heavier than controls, the group difference was adjusted for age, body mass index and sex and examined in post hoc matched subsamples. Results: Admission asprosin was 4.52 (2.94–5.89) ng/mL in patients and 3.55 (2.24–4.92) ng/mL in controls (p = 0.071); the ratio of geometric means adjusted for age, body mass index and sex was 1.17 (95% CI 0.85–1.61). Asprosin was higher in patients in post hoc age- and sex-matched pairs (median difference 1.91 ng/mL, 95% CI 0.24–3.78) but not in body mass index- and sex-matched pairs (0.96 ng/mL, −0.34 to 2.72). Asprosin changed little over five days and was not associated with moderately severe or severe AP (AUC 0.57, upper 95% confidence limits ≤0.71); only seven patients had severe AP. Conclusions: In this exploratory study, serum asprosin was modestly and non-significantly higher in patients with AP than in controls, and no statistically significant association with severity was detected. Residual confounding by age and body mass index, the exclusion of patients with diabetes or hypertriglyceridaemia (≥200 mg/dL) and the absence of in-house assay validation preclude firm conclusions. These data provide effect estimates for adequately powered, matched studies of asprosin in AP.

19 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OYOnur Selcuk Yigit
Onur Selcuk Yigit
MUMehmet Fatih Uzanulu
Mehmet Fatih Uzanulu
SGSELİN GENÇ
SELİN GENÇ
ISIbrahim Sahin
Ibrahim Sahin
Background/Objectives: This study aimed to investigate the relationship between serum endocan and total testosterone levels in male patients with prediabetes. Materials and Methods: This cross-sectional observational study included 37 men with prediabetes and 37 healthy male controls. In addition to routine laboratory tests, blood samples were collected to measure serum endocan levels using the enzyme-linked immunosorbent assay (ELISA), and total testosterone levels were analyzed using a chemiluminescence method. Results: Age did not differ significantly between the groups (p > 0.05). Body mass index (BMI), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), insulin, HbA1c, and serum endocan levels were significantly higher in the prediabetes group (BMI: p = 0.003; FPG: p < 0.001; PPG: p = 0.019; insulin: p = 0.007; HbA1c: p < 0.001; endocan: p = 0.012). No significant difference was observed in testosterone levels between the groups (p = 0.228). Conclusions: Elevated serum endocan levels in individuals with prediabetes may reflect early endothelial dysfunction associated with glycemic dysregulation. These findings suggest that endocan may serve as an exploratory biomarker of early vascular alterations in prediabetes. However, further large-scale and prospective studies are warranted to clarify its clinical relevance and potential role in risk stratification and the prediction of microvascular complications.

18 May 2026 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Closed access
ASAhmet Sarıcı
Ahmet Sarıcı
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
IKİrFan Kuku
İrFan Kuku
EKEmin KAYA
Emin KAYA
IBİlHami Berber
İlHami Berber
MAMusa Ak
Musa Ak
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.